PDF(Pubmed)
Abstract：
UNASSIGNED: To better understand what is most important to people living with human immunodeficiency virus (PLWH) when choosing their treatment. We assessed how PLWH trade off the potential risks and benefits of oral and long acting injectable (LAI) treatments.
UNASSIGNED: Firstly, in-depth interviews were conducted with 11 PLWH to develop a holistic understanding of experiences and determine attributes that contribute to treatment decision-making. Secondly, a discrete choice experiment (DCE) was used to understand the treatment preferences for PLWH with n = 99 PLWH aged 18 years or over with a diagnosis of human immunodeficiency virus (HIV) and who were currently using anti-retroviral therapy (ART). Study participants were presented with 12 scenarios and asked to select their preferred treatment among two hypothetical injectable treatment alternatives, \"injection 1\" and \"injection 2\" and their current oral ART treatment. The DCE data were modelled using a latent class model (LCM).
UNASSIGNED: The model revealed significant heterogeneity in preferences for treatment attributes among study participants. Two segments/classes of PLWH were identified. The first segment expressed a strong preference for their current oral treatment; the second segment showed strong preference for the injection treatment and for it to be administered in a GP clinic. Overall, out-of-pocket cost was the most important attribute for participants. One-third of PLWH were willing to switch to an LAI.
UNASSIGNED: Not all PLWH valued the same treatment attributes equally. Overall, out-of-pocket costs for treatments were considered by respondents as the most determining factor in making treatment choices. Results have important implications for healthcare policy and will serve to better inform patients and stakeholders involved in the treatment decision-making process about the treatment preferences of PLWH. Clinicians are encouraged to consider shared decision-making to establish the treatment course that best aligns with PLWH\'s treatment goals.
UNASSIGNED: Firstly, in-depth interviews were conducted with 11 PLWH to develop a holistic understanding of experiences and determine attributes that contribute to treatment decision-making. Secondly, a discrete choice experiment (DCE) was used to understand the treatment preferences for PLWH with n = 99 PLWH aged 18 years or over with a diagnosis of human immunodeficiency virus (HIV) and who were currently using anti-retroviral therapy (ART). Study participants were presented with 12 scenarios and asked to select their preferred treatment among two hypothetical injectable treatment alternatives, \"injection 1\" and \"injection 2\" and their current oral ART treatment. The DCE data were modelled using a latent class model (LCM).
UNASSIGNED: The model revealed significant heterogeneity in preferences for treatment attributes among study participants. Two segments/classes of PLWH were identified. The first segment expressed a strong preference for their current oral treatment; the second segment showed strong preference for the injection treatment and for it to be administered in a GP clinic. Overall, out-of-pocket cost was the most important attribute for participants. One-third of PLWH were willing to switch to an LAI.
UNASSIGNED: Not all PLWH valued the same treatment attributes equally. Overall, out-of-pocket costs for treatments were considered by respondents as the most determining factor in making treatment choices. Results have important implications for healthcare policy and will serve to better inform patients and stakeholders involved in the treatment decision-making process about the treatment preferences of PLWH. Clinicians are encouraged to consider shared decision-making to establish the treatment course that best aligns with PLWH\'s treatment goals.
摘要：
■为了更好地了解在选择治疗方法时对患有人类免疫缺陷病毒（PLWH）的人最重要的是什么。我们评估了PLWH如何权衡口服和长效注射（LAI）治疗的潜在风险和益处。
■首先，我们与11名PLWH进行了深入访谈,以全面了解经验,并确定有助于治疗决策的属性.其次,我们使用离散选择实验(DCE)来了解PLWH的治疗偏好,其中,年龄为18岁或以上、诊断为人类免疫缺陷病毒(HIV)且目前正在使用抗逆转录病毒治疗(ART)的PLWH为n=99例.研究参与者被介绍了12种情况，并要求在两种假设的可注射治疗替代方案中选择他们的首选治疗方法。“注射剂1”和“注射剂2”及其目前的口服ART治疗。使用潜在类模型(LCM)对DCE数据进行建模。
■该模型揭示了研究参与者对治疗属性偏好的显著异质性。确定了PLWH的两个区段/类别。第一部分对他们目前的口服治疗表现出强烈的偏好;第二部分对注射治疗和在GP诊所给药表现出强烈的偏好。总的来说,自付费用是参与者最重要的属性。三分之一的PLWH愿意改用LAI。
■并非所有PLWH都对相同的治疗属性赋予相同的价值。总的来说,受访者认为自付治疗费用是选择治疗方案的最决定性因素.结果对医疗保健政策具有重要意义，并将有助于更好地告知患者和参与治疗决策过程的利益相关者有关PLWH治疗偏好的信息。鼓励临床医生考虑共同决策，以建立最符合PLWH治疗目标的治疗过程。
■首先，我们与11名PLWH进行了深入访谈,以全面了解经验,并确定有助于治疗决策的属性.其次,我们使用离散选择实验(DCE)来了解PLWH的治疗偏好,其中,年龄为18岁或以上、诊断为人类免疫缺陷病毒(HIV)且目前正在使用抗逆转录病毒治疗(ART)的PLWH为n=99例.研究参与者被介绍了12种情况，并要求在两种假设的可注射治疗替代方案中选择他们的首选治疗方法。“注射剂1”和“注射剂2”及其目前的口服ART治疗。使用潜在类模型(LCM)对DCE数据进行建模。
■该模型揭示了研究参与者对治疗属性偏好的显著异质性。确定了PLWH的两个区段/类别。第一部分对他们目前的口服治疗表现出强烈的偏好;第二部分对注射治疗和在GP诊所给药表现出强烈的偏好。总的来说,自付费用是参与者最重要的属性。三分之一的PLWH愿意改用LAI。
■并非所有PLWH都对相同的治疗属性赋予相同的价值。总的来说,受访者认为自付治疗费用是选择治疗方案的最决定性因素.结果对医疗保健政策具有重要意义，并将有助于更好地告知患者和参与治疗决策过程的利益相关者有关PLWH治疗偏好的信息。鼓励临床医生考虑共同决策，以建立最符合PLWH治疗目标的治疗过程。
